GW&K Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $23.5M | Sell |
2,623,537
-261,143
| -9% | -$2.34M | 0.21% | 180 |
|
|
2025
Q1 | $21.6M | Sell |
2,884,680
-56,716
| -2% | -$425K | 0.2% | 190 |
|
|
2024
Q4 | $22.1M | Sell |
2,941,396
-336,204
| -10% | -$2.53M | 0.19% | 194 |
|
|
2024
Q3 | $24.9M | Sell |
3,277,600
-127,100
| -4% | -$966K | 0.21% | 186 |
|
|
2024
Q2 | $21M | Sell |
3,404,700
-49,208
| -1% | -$304K | 0.19% | 190 |
|
|
2024
Q1 | $17.5M | Buy |
3,453,908
+1,116,225
| +48% | +$5.67M | 0.15% | 205 |
|
|
2023
Q4 | $14M | Sell |
2,337,683
-233,180
| -9% | -$1.4M | 0.13% | 214 |
|
|
2023
Q3 | $18.2M | Sell |
2,570,863
-27,379
| -1% | -$194K | 0.18% | 188 |
|
|
2023
Q2 | $18.3M | Sell |
2,598,242
-5,689
| -0.2% | -$40K | 0.17% | 191 |
|
|
2023
Q1 | $21.7M | Buy |
2,603,931
+876,844
| +51% | +$7.31M | 0.21% | 169 |
|
|
2022
Q4 | $19.8M | Buy |
1,727,087
+309,947
| +22% | +$3.56M | 0.2% | 178 |
|
|
2022
Q3 | $17.9M | Buy |
+1,417,140
| New | +$17.9M | 0.2% | 177 |
|